Our complete semaglutide vs tirzepatide comparison guide covers this in detail, but here are the key differences in weight loss outcomes: Average Weight Loss Comparison Semaglutide (STEP-1 trial, 68 weeks): Average weight loss: 14.9% 69.1% lost 10% or more 50.5% lost 15% or more Tirzepatide (SURMOUNT-1 trial, 72 weeks at 15 mg dose): Average weight loss: 22.5% 89% lost 10% or more 78% lost 15% or more Tirzepatide shows higher average weight loss in clinical trials, though both medications demonstrate significant effectiveness
Zealthy Price is a subscription telehealth platform bundling medication, provider consultations, and digital coaching into tiered monthly costs ($99$399)
Overall, the consensus in clinician surveys is cautiously positive: those who use ePA give it high marks for speed and transparency ( [63] )
It is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2)
Wang S, Guo M, Ouyang H, Li X, Cordon-Cardo C, Kurimasa A et al
